Clinical research site organisation Velocity Clinical Research announced on Friday the appointment of Justin Starzyk as chief executive officer.
Paul Evans, PhD, will continue as chair of the board to support the company's growth strategy.
Starzyk joins Velocity with more than two decades of healthcare operating experience, including senior leadership roles at large, multisite healthcare services platforms. Most recently, Starzyk was president of United Urology Group, a urology management services organisation supporting a network of around 300 physicians and advanced practice providers with 2,000 teammates across 100 locations. Earlier in his career, he spent nearly a decade at DaVita in a range of operating and strategic growth-focused leadership roles.
Starzyk began his career at Abbott Laboratories / AbbVie in global pharmaceutical R&D.
Velocity Clinical Research appoints new CEO
Ipsen appoints new board director
Coiled Therapeutics completes enrolment in two AO-252 formulation cohorts
MaaT Pharma outlines potential Phase 3 development plan for MaaT013 after CHMP negative opinion
Kemp Proteins partners with NeuImmune to advance precision protein production
Bayer's Kerendia wins FDA approval for chronic kidney disease associated with type 1 diabetes
ProBio and Kun Tuo collaborate to deliver integrated CDMO-CRO solutions for advanced therapies
Myosin Therapeutics chosen for 2026-2027 NCI Investor Initiatives Showcase
Sobi and Innate confirm strategic partnership
Viatris receives Japanese approval for WAKIX in narcolepsy and sleep apnoea
WHO identifies SynAct Pharma's resomelagon among six dengue drug candidates
Japan approves subcutaneous Leqembi formulation for early Alzheimer's disease
Japan approves Lundbeck's eptinezumab for preventive migraine treatment